Latest From Advicenne SA
Having had a bid for accelerated assessment rejected by the EMA last year, the French biotech is getting a standard review for ADV7103 in dRTA patients and hopes to launch late 2020.
There's good news for Stemline Therapeutics on the EU fast-track front. At least three other companies, though, have had their requests rejected in recent months and Novartis is not saying whether a request it made was successful or not.
The first half of the year was pretty bleak for companies seeking fast-track review of their products in the EU. There has been much better news in the second half. The Pink Sheet tracks the winners and losers.
France's long-acting injectables technology company, MedinCell, which is collaborating with Teva on a Phase III long-acting risperidone formulation, has completed an IPO on Euronext Paris, giving a lift to its development plans.
- Therapeutic Areas
- Neurology, Nervous System
- Renal System
- Western Europe
- Parent & Subsidiaries
- Advicenne SA
- Senior Management
Luc-André Granier, MD, PhD, CEO & Med. Dir.
Caroline Roussel-Maupetit, Dir., Operations
Catherine Guittet, PhD, Dir., Clinical Research & Reg. Affairs
Catherine Martre, Head, Strategy & Comm. Dev.
- Contact Info
Phone: 466 05 54 20
2, rue Briçonnet
Nîmes, F-30 000
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.